Expert Ratings for Editas Medicine
Portfolio Pulse from Benzinga Insights
Analysts have provided various ratings for Editas Medicine (NASDAQ:EDIT) in the last quarter, with 2 bullish, 2 somewhat bullish, and 4 indifferent. The company has an average 12-month price target of $14.88, an increase of 1.43% from the previous average price target of $14.67.
August 04, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts' ratings for Editas Medicine are mixed, with an average 12-month price target of $14.88, indicating a potential upside.
The mixed ratings from analysts indicate uncertainty about the company's future performance. However, the increased average price target suggests that analysts see potential upside for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100